Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer - Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer

The ORR and DCR of RD were 28.8% (95% CI, 23.7-34.4) and 69.8% (95% CI, 64.1-75.0), respectively. Median PFS was 4.1 months (95% CI, 3.5-4.6); median OS was 11.6 months (95% CI, 9.9-13.9). Univariate and multivariate Cox regression analysis of OS showed that bone metastases at diagnosis, poor PS (2-3), and non-adenocarcinoma were independent poor prognostic factors.